1. Home
  2. PACK vs MNPR Comparison

PACK vs MNPR Comparison

Compare PACK & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ranpak Holdings Corp

PACK

Ranpak Holdings Corp

HOLD

Current Price

$3.45

Market Cap

485.2M

ML Signal

HOLD

Logo Monopar Therapeutics Inc.

MNPR

Monopar Therapeutics Inc.

HOLD

Current Price

$61.53

Market Cap

403.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PACK
MNPR
Founded
1972
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Containers/Packaging
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
485.2M
403.4M
IPO Year
2017
2019

Fundamental Metrics

Financial Performance
Metric
PACK
MNPR
Price
$3.45
$61.53
Analyst Decision
Buy
Strong Buy
Analyst Count
3
13
Target Price
$6.50
$101.42
AVG Volume (30 Days)
634.3K
145.1K
Earning Date
06-10-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$395,000,000.00
N/A
Revenue This Year
$11.99
N/A
Revenue Next Year
$8.16
N/A
P/E Ratio
N/A
N/A
Revenue Growth
7.08
N/A
52 Week Low
$2.91
$26.06
52 Week High
$6.31
$105.00

Technical Indicators

Market Signals
Indicator
PACK
MNPR
Relative Strength Index (RSI) 28.66 58.07
Support Level $3.34 $50.92
Resistance Level $3.79 $89.51
Average True Range (ATR) 0.32 3.09
MACD -0.16 1.10
Stochastic Oscillator 12.21 91.62

Price Performance

Historical Comparison
PACK
MNPR

About PACK Ranpak Holdings Corp

Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. Geographically, it derives a majority of its revenue from Europe/Asia. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

Share on Social Networks: